Kazia Therapeutics (KZIA) Stock: Buy, Sell, or Hold?
KZIA - Kazia Therapeutics Limited American Depositary Shares
$7.81
-0.26 (-3.22%)
▼
5d:
+7.72%
30d:
-20.14%
90d:
-36.04%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 06, 2026
12d
Get Alerted When KZIA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: KZIA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: KZIA shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: KZIA is currently trading at $7.81, which is considered oversold relative to its 30-day fair value range of $8.02 to $10.31.
Technical Outlook: Technically, KZIA is in a downtrend. Immediate support is located at $6.62, while resistance sits at $9.18. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: KZIA scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $29.54 (+278.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KZIA is in a downtrend. Immediate support is located at $6.62, while resistance sits at $9.18. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: KZIA scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $29.54 (+278.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.02 -
$10.31
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 278.3% below Wall St target ($29.54)
- BULLISH: Bottoming setup score 70/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$8.02 -
$10.31
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.62
Resistance Level
$9.18
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-667.52
Wall Street Target
$29.54
(+278.3%)
Revenue Growth (YoY)
312.4%
Share & Embed Analysis
Last updated: October 23, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KZIA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 49 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 47 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 52 HOLD |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$117 | 53 HOLD |
